On Nov 19, major Wall Street analysts update their ratings for $Syndax Pharmaceuticals (SNDX.US)$, with price targets ranging from $33 to $51.
Citi analyst Yigal Nochomovitz maintains with a buy rating, and adjusts the target price from $34 to $45.
Barclays analyst Peter Lawson maintains with a buy rating, and maintains the target price at $33.
TD Cowen analyst Phil Nadeau maintains with a buy rating.
Mizuho Securities analyst Salim Syed maintains with a buy rating.
H.C. Wainwright analyst Edward White maintains with a buy rating, and adjusts the target price from $49 to $51.
Furthermore, according to the comprehensive report, the opinions of $Syndax Pharmaceuticals (SNDX.US)$'s main analysts recently are as follows:
Following the FDA's approval of Revuforj, it's noted that prior concerns regarding the three-month extension were baseless. Additionally, the boxed warning for differentiation syndrome anticipated for Revuforj is likely to become standard across the broader menin-inhibitor class, representing no unique competitive disadvantage.
The company announced the FDA approval of REVUFORJ, revumenib, for relapsed or refractory acute leukemia with KMT2A translocation in adults and pediatric patients, which occurred 6-weeks before the expected PDUFA date. The safety and efficacy on the label align with expectations, and the recommendation for initial QTc monitoring during treatment is not seen as burdensome.
Here are the latest investment ratings and price targets for $Syndax Pharmaceuticals (SNDX.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间11月19日，多家华尔街大行更新了$Syndax Pharmaceuticals (SNDX.US)$的评级，目标价介于33美元至51美元。
花旗分析师Yigal Nochomovitz维持买入评级，并将目标价从34美元上调至45美元。
巴克莱银行分析师Peter Lawson维持买入评级，维持目标价33美元。
TD Cowen分析师Phil Nadeau维持买入评级。
瑞穗证券分析师Salim Syed维持买入评级。
H.C. Wainwright分析师Edward White维持买入评级，并将目标价从49美元上调至51美元。
此外，综合报道，$Syndax Pharmaceuticals (SNDX.US)$近期主要分析师观点如下：
在FDA批准Revuforj后，值得注意的是之前关于三个月延期的担忧是毫无根据的。此外，Revuforj预期的分化综合征包装警告有可能成为更广泛的脑膜抑制剂类别的标准，不会造成任何独特的竞争劣势。
该公司宣布FDA批准了REVUFORJ，用于成人和儿童复发性或难治性急性白血病伴有KMT2A易位，这发生在预期的PDUFA日期之前6周。标签上的安全性和有效性符合预期，并且治疗期间初次QTc监测的建议并不被视为繁琐。
以下为今日5位分析师对$Syndax Pharmaceuticals (SNDX.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
